Abstract:Objective To explore the efficacy and safety of autologous hematopoietic stem cell transplantation(AHST) in newly diagnosed type 1 diabetes mellitus.Methods Hematopoietic stem cells were mobilized with cyclophosphamide and granulocyte colonystimulating factor and then collected from peripheral blood by leukapheresis and cryopreserved.The cells were infused intravenously after conditioning with cyclophosphamide and rabbit antithymocyte globulin.To compare the daily dose of exogenous insulin requirements,serum levels of hemoglobin A1c,islet β-cell function during the mixed-meal tolerance test,and anti-islet antibody titers were measured before and at different times following AHST.The adverse effects during and after AHST were recorded.Results The patient has been free from insulin for more than 9 months since AHST.Serum levels of hemoglobin A1c were maintained at less than 7%,and islet β-cell function was greatly improved after AHST.There were no severe adverse effects such as myelosuppression and hemorrhagic cystitis.Conclusions Very encouraging results are obtained in the patient treated with AHST.There is definite therapeutic effects and safety in a short-term.But further follow-up is necessary to confirm the duration of insulin independence and the mechanisms of action of the procedure.

Therapeutic effect of autologous hematopoietic stem cell transplantation in one newly-diagnosed type 1 diabetic patient